Marijuana and Cannabinoids: Effects on infections, immunity, and AIDS

Cannabis Therapeutics in HIV/AIDS

Volumn , Issue , 2012, Pages 61-86

  Cabral, Guy A ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AIDS; Cannabinoid receptors; Cannabinoids; Delta 9 tetrahydrocannabinol; HIV; Immunity; Infections; Marijuana; THC

Indexed keywords

EID: 85071436256     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (111)

1. Achiron, A., S. Miron, V. Lavie, R. Margalit, and A. Biegon. 2000. Dexanabinol (HU-211) effect on experimental autoimmune encephalomyelitis: implications for the treatment of acute relapses of multiple sclerosis. J Neuroimmunol 102(1):26-31
2. Arata, S., C. Newton, T. Klein, and H. Friedman. 1991. Enhanced growth of Legionella pneumophila in tetrahydrocannabinol-treated macrophages. Proc Soc Exp Biol Med 199:65-7
3. Baczynsky, W. O. T., and A. M. Zimmerman. 1983. Effects of delta-9-tetrahydrocannabinol, cannabinol and cannabidiol on the immune system in mice. In vitro investigation using cultured mouse splenocytes. Pharmacology 26(1):12-9
4. Baldwin, G. C., D. P. Tashkin, D. M. Buckley, A. M., Park, S. M., Dubinett, and M. D. Roth. 1997. Marijuana and cocaine impair alveolar macrophage function and cytokine production. Am J Respir Crit Care Med 156(5):1606-13
5. Bass, R., D. Engelhard, V. Trembovler, and E. Shohami. 1996. A novel nonpsychotropic cannabinoid, HU-211, in the treatment of experimental pneumococcal meningitis. J Infect Dis 173:735-8
6. Berdyshev, E. V., E. Boichot, N. Germain, N. Allain, J. P. Anger, and V. Lagente. 1997. Influence of fatty acid ethanolamides and delta9-tetrahydrocannabinol on cytokine and arachidonate release by mononuclear cells. Eur J Pharmacol 330(2-3): 231-40
7. Bouaboula, M., C. Poinot-Chazel, J. Marchand, X. Canat, B. Bourrie, M. Rinaldi-Carmona, B. Calandra, G. Le Fur, and P. Casellas. 1996. Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression. Eur J Biochem 237(3):704-11
8. Bouaboula, M., C. Poinot-Chazel, B. Bourrie, X. Canat, B. Calandra, M. Rinaldi-Carmona, G. Le Fur, and P. Casellas. 1995. Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem J 312: 637-41
9. Bouaboula, M., M. Rinaldi, P. Carayon, C. Carillon, B. Delpech, D. Shire, G. Le Fur, and P. Casellas. 1993. Cannabinoid receptor expression in human leukocytes. Eur J Biochem 214:173-80
10. Buckley, N. E., K. L. McCoy, E. Mezey, T. Bonner, A. Zimmer, C. C. Felder, M. Glass, and A. Zimmer. 2000. Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. Eur J Pharmacol 396(2-3):141-9
11. Burnette-Curley, D., F. M. Marciano, K. Fischer, and G. A. Cabral. 1993. Delta-9-tetrahydrocannabinol inhibits cell contact-dependent cytotoxicity of Bacillus Calmétte-Guérin-activated macrophages. Int J Immunopharmacol 15:371-82
12. Burstein, S., J. Budrow, M. Debatis, S. A. Hunter, and A. Subramanian. 1994. Phospholipase participation in cannabinoid-induced release of free arachidonic acid. Biochem Pharmacol 48:1253-64
13. Cabral, G. A., and D. Dove Pettit. 1998. Drugs and immunity: Cannabinoids and their role in decreased resistance to infectious disease. J Neuroimmunol 83:116-23
14. Cabral, G. A., and K. Fischer-Stenger. 1994. Inhibition of macrophage inducible protein expression by delta-9-tetrahydrocannabinol. Life Sci 54:1831-44
15. Cabral, G. A., and E. M. Mishkin. 1989. Delta-9-tetrahydrocannabinol inhibits macrophage protein expression in response to bacterial immunomodulators. J Toxicol Environ Health 26:175-82
16. Cabral, G. A., P. J. McNerney, and E. M. Mishkin. 1987. Effect of micromolar concentrations of delta-9-tetrahydrocannabinol on herpes simplex virus type 2 replication in vitro. J Toxicol Environ Health 21(3):277-93
17. Cabral, G. A., J. C. Lockmuller, and E. M. Mishkin. 1986a. Delta-9-tetrahydrocannabinol decreases alpha/beta interferon response to herpes simplex virus type 2 in the B6C3F1 mouse. Proc Soc Exp Biol Med 181:305-11
18. Cabral, G., E. M. Mishkin, F. M. Marciano, R. E. Coleman, L. S. Harris, and A. E. Munson. 1986b. Effect of delta-9-tetrahydrocannabinol on herpes simplex virus type 2 vaginal infection in the guinea pig. Proc Soc Exp Biol Med 182:181-6
19. Caiaffa, W. T., D. Vlahov, N. M. D. Graham, J. Astemborski, L. Solomon, K. E. Nelson, and A. Munoz. 1994. Drug smoking, Pneumocystis carinii pneumonia, and immunosuppression increase risk of bacterial pneumonia in human immunodeficiency virus-seropositive injection drug users. Am J Respir Crit Care Med 150: 1493-8
20. Childers, S. R., and S. A. Deadwyler. 1996. Role of cyclic AMP in the actions of cannabinoid receptors. Biochem Pharmacol 52:819-27
21. Clements, D., G. A. Cabral, and K. L. McCoy. 1996. Delta-9-tetrahydrocannabinol selectively inhibits macrophage co-stimulatory activity and down-regulates heat-stable antigen expression. J Pharmacol Exp Ther 277:1315-21
22. del Arco, I., R. Munoz, F. Rodriguez De Fonseca, L. Escudero, J. L. Martin-Calderon, M. Navarro, and M. A. Villanua. 2000. Maternal exposure to the synthetic cannabinoid HU-210: effects on the endocrine and immune systems of the adult male offspring. Neuroimmunomodulation 7(1):16-26
23. Derocq, J. M., O. Jbilo, M. Bouaboula, M. Segui, C. Clere, and P. Casellas. 2000. Genomic and functional changes induced by the activation of the peripheral cannabinoid receptor CB2 in the promyelocytic cells HL-60. Possible involvement of the CB2 receptor in cell differentiation. J Biol Chem 275(21):15621-8
24. Derocq, J. M., M. Segui, J. Marchand, G. Le Fur, and P. Casellas. 1995. Cannabinoids enhance human B-cell growth at low nanomolar concentrations. FEBS Letters 369:177-82
25. Desoize, B., C. Leger, and G. G. Nahas. 1979. Plasma membrane inhibition of macromolecular precursor transport by THC. Biochem Pharmacol 28:1113-8
26. Dewey, W. L. 1986. Cannabinoid pharmacology. Pharmacol Rev 38(2):151-78
27. DiFranco, M. J, H. W. Sheppard, D. J. Hunter, T. D. Tosteson, and M. S. Ascher. 1996. The lack of association of marijuana and other recreational drugs with progression to AIDS in the San Francisco Men's Health Study. Ann Epidemiol 6(4):283-9
28. Dove Pettit, D. A., D. L. Anders, M. P. Harrison, and G. A. Cabral. 1996. Cannabinoid receptor expression in immune cells. Adv Exp Med Biol 402:119-29
29. Drath, D. B., J. M. Shorey, L. Price, and G. L. Huber. 1979. Metabolic and functional characteristics of alveolar macrophages recovered from rats exposed to marijuana smoke. Infect Immun 25:268-72
30. Facci, L., R. Dal Tosso, S. Romanello, A. Buriani, S. D. Skaper, and A. Leon. 1995. Mast cells express a peripheral receptor and differential sensitivity to anandamide and palmitoylethanolamide. Proc Natl Acad Sci USA 92:3376-80
31. Faubert, B. L., and N. E. Kaminski. 2000. AP-1 activity is negatively regulated by cannabinol through inhibition of its protein components, c-fos and c-jun. J Leukoc Biol 67(2):259-66
32. Felder, C. C., K. E. Joyce, E. M. Briley, J. Mansouri, K. Mackie, O. Blond, Y. Lai, A. L. Ma, and R. L. Mitchell. 1995. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol 48:443-50
33. Felder, C. C., J. S. Veluz, H. L. Williams, E. M. Briley, and L. A. Matsuda. 1992. Cannabinoid agonists stimulate both receptor-and non-receptor-mediated signal transduction pathways in cells transfected with and expressing cannabinoid receptor clones. Mol Pharmacol 42:838-45
34. Fischer-Stenger, K., A. W. Updegrove, and G. A. Cabral. 1992. Delta-9-tetrahydrocannabinol decreases cytotoxic T lymphocyte activity to herpes simplex virus type 1-infected cells. Proc Soc Exp Biol Med 200:422-30
35. Friedman, H., and T. W. Klein. 1999. Marijuana and immunity. Sci Med 6(2):12-21. Galiègue, S., S. Mary, J. Marchand, D. Dussosoy, D. Carrière, P. Carayon, M
36. Galiègue, S., S. Mary, J. Marchand, D. Dussosoy, D. Carrière, P. Carayon, M. Bouaboula, D. Shire, G. Le Fur, and P. Casellas. 1995. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 232:54-61
37. Gallily, R., A. Yamin, Y. Waksmann, H. Ovadia, J. Weidenfeld, A. Bar-Joseph, A. Biegon, R. Mechoulam, and E. Shohami. 1997. Protection against septic shock and suppression of tumor necrosis factor alpha and nitric oxide production by dexanabinol (HU-211), a nonpsychotropic cannabinoid. J Pharmacol Exp Ther 283(2): 918-24
38. Gomez Del Pulgar, T., G. Velasco, and M. Guzman. 2000. The CB1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt. Biochem J 347:369-73. Gross, A., A. Terraza, J. Marchant, M. Bouaboula, S. Ouahrani-Bettache, J. P. Liautard
39. Gross, A., A. Terraza, J. Marchant, M. Bouaboula, S. Ouahrani-Bettache, J. P. Liautard, P. Casellas, and J. Dornand. 2000. A beneficial aspect of a CB1 cannabinoid receptor antagonist: SR141716A is a potent inhibitor of macrophage infection by the intracellular pathogen Brucella suis. J Leukoc Biol 67(3): 335-44
40. Gross, G., A. Roussaki, H. Ikenberg, and N. Dress. 1991. Genital warts do not respond to systemic recombinant interferon alpha-2a treatment during cannabis consumption. Dermatologica 183:203-7
41. Gupta, G., M. Grieco, and P. Cushman. 1974. Impairment of rosette-forming T-lymphocytes in chronic marihuana smokers. New Eng J Med 291:874-6
42. Herring, A. C., and N. E. Kaminski. 1999. Cannabinol-mediated inhibition of nuclear factor-kappa B, cAMP response element-binding protein, and interleukin-2 secretion by activated thymocytes. J Pharmacol Exp Ther 291(3):1156-63
43. Howlett, A. C. 1985. Cannabinoid inhibition of adenylate cyclase. Biochemistry of the response in neuroblastoma cell membranes. Mol Pharmacol 27:429-36
44. Howlett, A. C. 1984. Inhibition of neuroblastoma adenylate cyclase by cannabinoid and nantradol compounds. Life Sci 35:1803-10
45. Howlett, A. C., and R. M. Fleming. 1984. Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma cell membranes. Mol Pharmacol 26:532-8
46. Howlett, A. C., T. M. Champion, G. H. Wilken, and R. Mechoulam. 1990. Stereochemical effects of 11-OH-delta 8-tetrahydrocannabinol-dimethylheptyl to inhibit adenyl cyclase and bind to the cannabinoid receptor. Neuropharmacol 29:161-5
47. Howlett, A. C., J. M. Qualy, and L. L. Khachchatrian. 1986. Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs. Mol Pharmacol 29: 307-13
48. Jeon, Y. J., K. H. Yang, J. T. Pulaski, and N. E. Kaminski. 1996. Attenuation of inducible nitric oxide gene expression by δ9-tetrahydrocannabinol is mediated through the inhibition of nuclear factor-κB/rel activation. Mol Pharmacol 50:334-41
49. Johnson, T. E., R. R. Casiano, J. W. Kronish, D. T. Tse, M. Meldrum, and W. Chang. 1999. Sino-orbital aspergillosis in acquired immunodeficiency syndrome. Arch Ophthalmol 117(1):57-64
50. Kaminski, N. E., M. E. Abood, F. K. Kessler, B. R. Martin, and A. R. Schatz. 1992. Identification of a functionally relevant cannabinoid receptor on mouse spleen cells that is involved in cannabinoid-mediated immune modulation. Mol Pharmacol 42:736-42
51. Kaminski, N. E., W. S. Koh, K. H. Yang, M. Lee, and F. K. Kessler. 1994. Suppression of the humoral immune response by cannabinoids is partially mediated through inhibition of adenylate cyclase by a pertussis toxin-sensitive G-protein coupled mechanism. Biochem Pharmacol 48:1899-908
52. Kawakami, Y., T. W. Klein, C. Newton, J. Y. Djeu, S. Specter, and H. Friedman. 1988. Suppression of delta-9-tetrahydrocannabinol of interleukin 2-induced lymphocyte proliferation and lymphokine-activated killer cell activity. Int J Immunopharmacol 10:485-8
53. Klein, T. W., C. A. Newton, N. Nakachi, and H. Friedman. 2000. Delta 9-tetrahydrocannabinol treatment suppresses immunity and early IFN-gamma, IL-12, and IL-12 receptor beta 2 responses to Legionella pneumophila infection. J Immunol 164(12):6461-6
54. Klein, T. W., C. Newton, and H. Friedman. 1994. Resistance to Legionella pneumophila suppressed by the marijuana component, tetrahydrocannabinol. J Infect Dis 169:1177-9
55. Klein, T., C. Newton, R. Widen, and H. Friedman. 1993. Delta-9-tetrahydrocannabinol injection induces cytokine-mediated mortality of mice infected with Legionella pneumophila. J Pharmacol Exp Ther 267:635-40
56. Klein, T. W., Y. Kawakami, C. Newton, and H. Friedman. 1991. Marijuana components supress induction and cytolytic function of murine cytotoxic T cells in vitro and in vivo. J Toxicol Environ Health 32:465-77
57. Klein, T. W. and H. Friedman. 1990. Drugs of abuse and immune function. In R. R. Watson (Ed.). Boca Raton:CRC Press
58. Klein, T. W., C. Newton, and H. Friedman. 1987. Inhibition of natural killer cell function by marijuana components. J Toxicol Environmental Health 20:321-32
59. Klein, T. W., C. Newton, R. Widen, and H. Friedman. 1985. The effect of delta-9-tetrahydrocannabinol and 11-hydroxy-delta 9-tetrahydrocannabinol on T-lymphocyte and B-lymphocyte mitogen responses. J Immunopharmacol 7:451-66
60. Klykken, P. C., S. H. Smith, J. A. Levy, R. Razdan, and A. E. Munson. 1977. Immunosuppressive effects of 8,9-epoxyhexahydrocannabinol (EHHC). J Pharmacol Exp Ther 201:573-9
61. Kusher, D. I., L. O. Dawson, A. C. Taylor, and J. Y. Djeu. 1994. Effect of the psychoactive metabolite of marijuana, delta-9-tetrahydrocannabinol (THC), on the synthesis of tumor necrosis factor by large granular lymphocytes. Cellular Immunol 154(1):99-108
62. Lee, M., K. H.Yang, and N. E. Kaminski. 1995. Effects of putative receptor ligands, anandamide and 2-arachidonyl-glycerol, on immune function in B6C3F1 mouse splenocytes. J Pharmacol Exp Ther 275:529-36
63. Lopez-Cepero, M., M. Friedman, T. Klein, and H. Friedman. 1986. Tetrahydrocannabinol-induced suppression of macrophage spreading and phagocyte activity in vitro. J Leukoc Biol 39: 679-86
64. Lynn, A. B., and M. Herkenham. 1994. Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: implications for receptor-mediated immune modulation by cannabinoids. J Pharmacol Exp Ther 268:1612-23
65. Mackie, K., and B. Hille. 1992. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc Natl Acad Sci USA 89:3825-9
66. Malfait, A. M., R. Gallily, P. F. Sumariwalla, A. S. Malik, E. Andreakos, R. Mechoulam, and M. Feldmann. 2000. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci USA 97(17):9561-6
67. Mann, P. E. G., A. B. Cohen, T. N. Finley, and A. J. Ladman. 1971. Alveolar macrophages. Structural and functional differences between non-smokers and smokers of marijuana in vitro. Lab Invest 25:111-20
68. Massi, P., D. Fuzio, D. Vigano, P. Sacerdote, and D. Parolaro. 2000. Relative involvement of cannabinoid CB(1) and CB(2) receptors in Delta(9)-tetrahydrocannabinol-induced inhibition of natural killer activity. Eur J Pharmacol 387(3):343-7
69. Massi, P., P. Sacerdote, W. Ponti, D. Fuzio, B. Manfredi, D. Vigano, T. Rubino, M. Bardotti, and D. Parolaro. 1998. Immune function alterations in mice tolerant to delta-9-tetrahydrocannabinol: functional and biochemical parameters. J Neuroimmunol 92(1-2):60-6
70. Matsuda, L. A., S. J. Lolait, M. J. Brownstein, A. C. Young, and T. I. Bonner. 1990. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346:561-4
71. Matveyeva, M., C. B. Hartman, M. T. Harrison, G. A. Cabral, and K. L. McCoy. 2000. Delta (9)-tetrahydrocannabinol selectively increases aspartyl cathepsin D proteolytic activity and impairs lysozyme processing by macrophages. Int J Immunopharmacol 22(5):373-81
72. McCoy, K. L., D. Gainey, and G. A. Cabral. 1995. δ9-Tetrahydrocannabinol modulates antigen processing by macrophages. J Pharmacol Exp Ther 273:1216-23
73. McCoy, K. L., M. Matveyeva, S. J. Carlisle, and G. A. Cabral. 1999. Cannabinoid inhibition of the processing of intact lysozyme by macrophages: Evidence for CB2 receptor participation. J Pharmacol Exp Ther 289:1620-5
74. Miller, J. M. Jr., and C. Goodridge. 2000. Antenatal marijuana use is unrelated to sexually transmitted infections during pregnancy. Infect Dis Obstet Gynecol 8(3-4): 155-7
75. Mishkin, E. M., and G. Cabral. 1985. Delta-9-tetrahydrocannabinol decreases host resistance to herpes simplex virus type 2 vaginal infection in the B6C3F1 mouse. J Gen Virol 66:2539-49
76. Molina-Holgado, F., A. Lledo, and C. Guaza. 1997. Anandamide suppresses nitric oxide and TNF-alpha responses to Theiler's virus or endotoxin in astrocytes. Neuroreport 8(8):1929-33
77. Morahan, P. S., P. C. Klykken, S. H. Smith, L. S. Harris, and A. E. Munson 1979. Effects of cannabinoids on host resistance to Listeria monocytogenes and herpes simplex virus. Inf Immun 23:670-4
78. Munro, S., K. L. Thomas, and M. Abu-Shaar. 1993. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365:61-5
79. Munson, A. E., J. A. Levy, L. S. Harris, and W. L. Dewey. 1976. Effects of delta 9-tetrahydrocannabinol on the immune system. The Pharmacology of Marijuana. Braude, M. C., and S. Szara. New York: Raven Press
80. Munson, A. E., and K. O. Fehr.1983. Immunological Effects of Cannabis. Cannabis and Health Hazards. Fehr, K. O. and H. Kalant. Toronto: Alcoholism and Drug Addiction Research Foundation
81. Nahas, G. G., A. Morishima, and B. Desoize. 1977. Effects of cannabinoids on macromolecular synthesis and replication of cultured lymphocytes. Fed Proc 36:1748-52
82. Nahas, G. G., and E. F. Osserman. 1991. Altered serum immunoglobulin concentration in chronic marijuana smokers. Adv Exp Med Biol 288:25-32
83. Nahas, G. G., N. Suciu-Foca, J. P. Armand, and A. Morishima 1974. Inhibition of cellular mediated immunity in marihuana smokers. Science 183:419-20
84. Netzeband, J. G., S. M. Conroy, K. L. Parsons, and D. L. Gruol. 1999. Cannabinoids enhance NMDA-elicited Ca2+ signals in cerebellar granule neurons in culture. J Neurosci 19:8765-77
85. Newton, C., T. Klein, and H. Friedman. 1998. The role of macrophages in THC-induced alteration of the cytokine network. Adv Exp Med Biol 437:207-14
86. Newton, C. A., T. W. Klein, and H. Friedman. 1994. Secondary immunity to Legionella pneumophila and Th1 activity are suppressed by delta-9-tetrahydrocannabinol injection. Inf Immun 62:4015-20
87. Noe, S. N., S. B. Nyland, K. Ugen, H. Friedman, and T. W. Klein. 1998. Cannabinoid receptor agonists enhance syncytia formation in MT-2 cells infected with cell free HIV-1MN. Adv Exp Med Biol 437:223-9
88. Patel, V., M. Borysenko, M. S. A. Kumar, and W. J. Millard. 1985. Effects of acute and subchronic delta-9-tetrahydrocannabinol administration on the plasma catecholamine, beta-endorphin, and corticosterone levels and splenic natural killer cell activity in rats. Proc Soc Exp Biol Med 180:400-4
89. Persaud, N. E., W. Klaskala, T. Tewari, J. Schultz, and M. Baum. 1999. Drug use and syphilis. Co-factors for HIV transmission among commercial sex workers in Guyana. West Indian Med J 48(2):52-6
90. Peterson, B. H., J. Graham, and L. Lemberger. 1976. Marihuana, tetrahydrocannabinol and T-cell function. Life Sci 19:395-400
91. Pross, S. H., Y. Nakano, R. Widen, S. McHugh, C. A. Newton, T. W. Klein, and H. Friedman. 1992. Differing effects of delta-9-tetrahydrocannabinol (THC) on murine spleen cell populations dependent upon stimulators. Int J Immunopharmacol 14: 1019-27
92. Ramarathinam, L., S. Pross, O. Plescia, C. Newton, R. Widen, and H. Friedman. 1997. Differential immunologic modulatory effects of tetrahydrocannabinol as a function of age. Mech Ageing Dev 96(1-3):117-26
93. Rinaldi-Carmona, M., F. Barth, M. Héaulme, D. Shire, B. Calandra, C. Congy, S. Martinez, J. Maruani, G. Néliat, D. Caput, P. Ferrara, P. Soubrié, J. C. Breliére, and G. Le Fur. 1994. Sr141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Letters 350:240-4
94. Rinaldi-Carmona, M., F. Barth, J. Millan, J. M. Derocq, P. Casellas, C. Congy, D. Oustric, M. Sarran, M. Bouaboula, B. Calandra, M. Portier, D. Shire, J. C. Breliére, and G. Le Fur. 1998. SR144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther 284:644-50
95. Shohami, E., R. Gallily, R. Mechoulam, R. Bass, and T. Ben-Hur. 1997. Cytokine production in the brain following closed head injury: dexanabinol (HU-211) is a novel TNF-alpha inhibitor and an effective neuroprotectant. J Neuroimmunol 72(2): 169-77
96. Simeon, D. T., B. Bain, G. E. Wyatt, E. LeFranc, H. Ricketts, C. C. Chambers, and M. B. Tucker. 1996. Characteristics of Jamaicans who smoke marijuana before sex and their risk status for sexually transmitted diseases. West Indian Med J 45(1):9-13
97. Smith, S. R., C. Terminelli, and G. Denhardt. 2000. Effects of cannabinoid receptor agonist and antagonist ligands on production of inflammatory cytokines and anti-inflammatory interleukin-10 in endotoxemic mice. J Pharmacol Exp Ther 293(1): 136-50
98. Smith, S. H., L. S. Harris, I. M. Uwaydah, and A. E. Munson. 1978. Structure-activity relationships of natural and synthetic cannabinoids in suppression of humoral and cell-mediated immunity. J Pharmacol Exp Ther 207:165-70
99. Specter, S. C., T. W. Klein, C. Newton, M. Mondragon, R. Widen, and H. Friedman. 1986. Marijuana effects on immunity:suppression of human natural killer cell activity by delta-9-tetrahydrocannabinol. Int J Immunopharmacol 8:741-5
100. Specter, S., G. Lancz, G. Westrich, and H. Friedman. 1991. Delta-9-tetrahydrocannabinol augments murine retroviral induced immunosuppression and infection. Int J Immunopharmacol 13:411-7
101. Srivastava, M. D., B. I. Srivastava, and B. Brouhard. 1998. Delta-9-tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells. Immunopharmacology 40(3):179-85
102. Stefano, G. B., M. Salzet, and T. V. Bilfinger. 1998. Long-term exposure of human blood vessels to HIV gp120, morphine, and anandamide increases endothelial adhesion of monocytes: uncoupling of nitric oxide release. J Cardiovasc Pharmacol 31(6):862-8
103. Stefano, G. B., Y. Liu, and M. S. Goligorsky. 1996. Cannabinoid receptors are coupled to nitric oxide release in invertebrate immunocytes, microglia, and human monocytes. J Biol Chem 271: 19238-42
104. Timpone, J. G., D. J. Wright, N. Li, M. J. Egorin, M. E. Enama, J. Mayers, and J. Galetto. 1997. The safety and pharmokinetics of single-agent and combination therapy with Megestrol acetate and Dronabinol for the treatment of HIV wasting syndrome. AIDS Res Hum Retroviruses 13:305-15
105. Tindall, B., D. A. Cooper, B. Donovan, T. Barnes, C. R. Philpot, J. Gold, and R. Penny. 1988. The Sydney AIDS Project: development of acquired immunodeficiency syndrome in a group of HIV seropositive homosexual men.AustNZJMed 18(1):8-15
106. Waksman, Y., J. M. Olson, S. J. Carlisle, and G. A. Cabral. 1999. The central cannabinoid receptor (CB1) mediates inhibition of nitric oxide production by rat microglial cells. J Pharmacol Exp Ther 288:1357-66
107. Wallace, J. M., R. Lim, B. L. Browdy, P. C. Hopewell, J. Glassroth, M. J. Rosen, L. B. Reichman, and P. A. Kvale.1998. Risk factors and outcomes associated with identification of Aspergillus in respiratory specimens from persons with HIV disease. Pulmonary complications of HIV infection study group. Chest 114(1):131-7
108. Whitfield, R. M., L. M. Bechtel, and G. H. Starich. 1997. The impact of ethanol and Marinol/marijuana usage on HIV+/AIDS patients undergoing azidothymidine, azidothymidine/dideoxycytidine, or dideoxyinosine therapy. Alcohol Clin Exp Res 21(1): 122-7
109. Wing, D. R., J. T. A. Leuschner, G. A. Brent, D. J. Harvey, and W. D. M. Paton. 1985. Quantification of in vivo membrane associated delta-9-tetrahydrocannabinol and its effects on membrane fluidity. Proceedings of the 9th International Congress of Pharmacology 3rd satellite symposium on cannabis. Harvey, D. J. Oxford: IRL Press
110. Zhu, L. X., S. Sharma, M. Stolina, B. Gardner, M. D. Roth, D. P. Tashkin, and S. M. Dubinett. 2000. Delta-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway. J Immunol 165(1):373-80
111. Zimmerman, S., A. M. Zimmerman, I. L. Cameron, and H. L. Lawrence. 1977. Delta1-tetrahydrocannabinol, cannabidiol and cannabinol effects on the immune response of mice. Pharmacology 15:10-23